Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.74 (market cap $29.60B), while Booz Allen Hamilton Holding Corporation trades at $78.37 (market cap $9.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAH | |
|---|---|---|
Market Cap | $29.60B | $9.45B |
Sector | Health | Industrials |
52-Week High | $491.22 | $111.63 |
52-Week Low | $205.48 | $59.71 |
Enterprise Value | $27.56B | $13.07B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Booz Allen Hamilton (BAH) trades at $77.93, up 0.04% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 7.01% net margin and 68.11% ROE, while valuation ratios like P/E of 12.33 and P/S of 0.86 appear attractive. Recent Q2 2026 earnings beat estimates at $1.81 per share, and the company maintains consistent dividend payments, reflecting financial stability.
Outlook remains positive with analyst consensus price target of $84.67, though risks include high debt levels and civil revenue weakness. Growth in national security and AI investments offers upside, but investors should monitor leverage and sector-specific headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
